Therapy with Omalizumab for Patients with Severe Allergic Asthma Improves Asthma Control and Reduces Overall Healthcare Costs

Overview

Journal Ir J Med Sci

Specialty General Medicine

Date 2011 May 11

PMID 21557095

Citations 12

Authors

R W Costello

D A LONG

S Gaine

T Mc Donnell

J J Gilmartin

S J Lane

Affiliations

Soon will be listed here.

Abstract

Background: Patients with asthma who have persistent symptoms despite treatment with inhaled steroids and long-acting beta agonists are considered to have severe asthma. Omalizumab is a monoclonal antibody directed against IgE, which is used as an add-on treatment for patients who have severe persistent allergic asthma.

Aims: The aim of this study was to assess the clinical benefit and healthcare utilisation of patients who responded to omalizumab therapy and to establish an overall cost implication.

Methods: This was an observational retrospective cohort study designed to investigate the effect of omalizumab on exacerbations of asthma before and after 6 months of treatment in Irish patients.

Results: Centres who had treated patients with severe allergic asthma for the 6 months prior and post omalizumab treatment were audited with a standardised assessment tool. Sixty-three (32 male) patients were studied. In the 6 months prior to omalizumab 41 of 63 (66%) had been hospitalised, and this fell to 15 of 63 (24%), p < 0.0001 in the 6 months after treatment was started. Hospital admissions reduced from 2.4 ± 0.41 to 0.8 ± 0.37 and the mean number of bed days occupied was reduced from 16.6 ± 2.94 to 5.3 ± 2.57 days, p < 0.001. The number of oral corticosteroid doses used fell from 3.1 ± 0.27 to 1.2 ± 0.17, p < 0.001. The overall cost saving per omalizumab responder patients for 6 months was <euro>834.

Conclusions: Six months therapy with omalizumab reduced the number of bed days, the number of hospitalisations and the use of oral corticosteroids compared to the 6 months prior to commencement. Despite the cost of the additional therapy there were overall savings in health costs.

Citing Articles

Clinical utility of anti-interleukin 5 monoclonal therapy in asthma using a national, centralised, outcome-based system of drug access.

OLeary C, Schultz C, Walsh C, Adams R, Casey D, Lane S BMJ Open Respir Res. 2022; 9(1).

PMID: 36167473 PMC: 9516070. DOI: 10.1136/bmjresp-2022-001341.

Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma.

Jung J, Park H, Park C, Cho S, Choi I, Moon H Korean J Intern Med. 2021; 36(4):1001-1013.

PMID: 34237826 PMC: 8273830. DOI: 10.3904/kjim.2020.549.

Cost-effectiveness of fractional exhaled nitric oxide (FeNO) measurement in predicting response to omalizumab in asthma.

Brooks E, Massanari M, Hanania N, Weiner D Clinicoecon Outcomes Res. 2019; 11:301-307.

PMID: 31114270 PMC: 6497051. DOI: 10.2147/CEOR.S177207.

Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study.

Entrenas Costa L, Casas-Maldonado F, Soto Campos J, Padilla-Galo A, Levy A, Alvarez Gutierrez F Pharmacoecon Open. 2019; 3(3):333-342.

PMID: 30684255 PMC: 6710309. DOI: 10.1007/s41669-019-0117-4.

Anti-IgE therapy for asthma: an audit at atertiary care centre in Saudi Arabia.

Weheba I, Abdelsayed A, Arnaout R, Zeitouni M, Mobaireek K, AlHarthi T Ann Saudi Med. 2018; 38(6):439-444.

PMID: 30531179 PMC: 6302986. DOI: 10.5144/0256-4947.2018.439.

References

Moore W, Bleecker E, Curran-Everett D, Erzurum S, Ameredes B, Bacharier L . Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol. 2007; 119(2):405-13. PMC: 2837934. DOI: 10.1016/j.jaci.2006.11.639. View

Pinto J, Mehta N, DiTineo M, Wang J, Baroody F, Naclerio R . A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology. 2010; 48(3):318-24. DOI: 10.4193/Rhino09.144. View

Rodrigo G, Neffen H, Castro-Rodriguez J . Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2010; 139(1):28-35. DOI: 10.1378/chest.10-1194. View

Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A . "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med. 2009; 103(11):1633-42. DOI: 10.1016/j.rmed.2009.06.014. View

Busse W, Corren J, Lanier B, McAlary M, Fowler-Taylor A, Cioppa G . Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001; 108(2):184-90. DOI: 10.1067/mai.2001.117880. View

Plewako H, Arvidsson M, Petruson K, Oancea I, Holmberg K, Adelroth E . The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol. 2002; 110(1):68-71. DOI: 10.1067/mai.2002.125488. View

Heaney L, Brightling C, Menzies-Gow A, Stevenson M, Niven R . Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry. Thorax. 2010; 65(9):787-94. PMC: 2975949. DOI: 10.1136/thx.2010.137414. View

Fahy J, Fleming H, Wong H, Liu J, Su J, Reimann J . The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med. 1997; 155(6):1828-34. DOI: 10.1164/ajrccm.155.6.9196082. View

Lloyd A, Price D, Brown R . The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J. 2007; 16(1):22-7. PMC: 6634181. DOI: 10.3132/pcrj.2007.00002. View

10.

van den Berge M, Pauw R, de Monchy J, van Minnen C, Postma D, Kerstjens H . Beneficial effects of treatment with anti-IgE antibodies (Omalizumab) in a patient with severe asthma and negative skin-prick test results. Chest. 2011; 139(1):190-3. DOI: 10.1378/chest.10-0128. View

11.

Holgate S, Smith N, Massanari M, Jimenez P . Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy. 2009; 64(12):1728-36. DOI: 10.1111/j.1398-9995.2009.02201.x. View

12.

Djukanovic R, Wilson S, Kraft M, Jarjour N, Steel M, Chung K . Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004; 170(6):583-93. DOI: 10.1164/rccm.200312-1651OC. View

13.

Bradding P, Green R . Subclinical phenotypes of asthma. Curr Opin Allergy Clin Immunol. 2009; 10(1):54-9. DOI: 10.1097/ACI.0b013e32833489a9. View

14.

Royce S, Tang M . The effects of current therapies on airway remodeling in asthma and new possibilities for treatment and prevention. Curr Mol Pharmacol. 2009; 2(2):169-81. DOI: 10.2174/1874467210902020169. View

15.

Schleich F, Manise M, Louis R . [Omralizumab (Xolair) in severe persistent allergic asthma]. Rev Med Liege. 2009; 64(5-6):313-7. View

16.

Firszt R, Kraft M . Pharmacotherapy of severe asthma. Curr Opin Pharmacol. 2010; 10(3):266-71. PMC: 4390052. DOI: 10.1016/j.coph.2010.04.010. View

17.

Molimard M, de Blay F, Didier A, Le Gros V . Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med. 2007; 102(1):71-6. DOI: 10.1016/j.rmed.2007.08.006. View